NCT03976245RecruitingPhase 4
Advanced Therapeutics in Rheumatoid Arthritis (RA)
Source: ClinicalTrials.gov · Last updated 29 Nov 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study will evaluate the retention rates of two advanced therapies, Tumour Necrosis Factor (TNF) and Janus kinase inhibitor (JAK) in the treatment of adults with Rheumatoid Arthritis (RA) over a two year period. It will also examine the ability to embed a clinical trial in a clinical situation using an electronic medical record (EMR).
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 144 (estimated)
- First submitted
- 3 Jun 2019
- Start date
- 1 Mar 2020
- Primary completion date
- Mar 2025
- Lead sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- Diseases
- Rheumatoid arthritis
- NCT number
- NCT03976245
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 144
- From 1 Mar 2020 to the primary completion date, Mar 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- previous use of an advanced therapeutic (biologic or JAK kinase inhibitor)
Other illness
- active serious infection
- active Tuberculosis
- current cancer
Age
- less than 18 years of age
Other
- no contraindication to etanercept or tofacitinib
- multiple sclerosis
- lymphoma ever
- unable to provide consent
Who the study is looking for
- patients with RA who meet criteria for obtaining an advanced therapeutic through usual care
- active RA with 5 or more swollen joints
- seropositive
- presence of erosions
- failure of methotrexate and hydroxychloroquine and sulfasalazine
- failure of Leflunomide
- -\> or equal to 18 years
- able to provide consent
- able to attend usual follow up visits
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Rheumatology Clinic, St. Joseph's Health Care Coordinator of this site? Confirm its status | London | Canada | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.